Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) Depreciation & Amortization (IS) (2024 - 2025)

Iovance Biotherapeutics has reported Depreciation & Amortization (IS) over the past 5 years, most recently at $9.5 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (IS) at $9.5 million for Q4 2025, up 3.98% from a year ago — trailing twelve months through Dec 2025 was $37.4 million (up 97.87% YoY), and the annual figure for FY2025 was $35.9 million, down 4.43%.
  • Depreciation & Amortization (IS) for Q4 2025 was $9.5 million at Iovance Biotherapeutics, up from $9.0 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (IS) for IOVA hit a ceiling of $9.7 million in Q3 2024 and a floor of $9.0 million in Q3 2025.